Trials / Completed
CompletedNCT00443443
A Study of the Safety of Rituxan in Patients With Rheumatoid Arthritis After an Inadequate Response to Previous Anti-TNF Therapy (SUNSTONE)
A Long-Term Study of the Safety of Rituxan in Patients With Rheumatoid Arthritis After an Inadequate Response to Previous Anti-TNF Therapy (SUNSTONE)
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 1,026 (actual)
- Sponsor
- Genentech, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is an observational study designed to follow patients with RA who have had an inadequate response to one or more anti-TNF therapies and who will receive Rituxan. Approximately 1000 patients in the United States with RA who have had an inadequate response to anti-TNF therapies and who will receive Rituxan therapy will be recruited. There is no protocol mandated treatment assignment in this study. Patients will be evaluated and treated according to their physician's standard practice and discretion.
Conditions
Timeline
- Start date
- 2007-01-01
- Primary completion
- 2013-09-01
- Completion
- 2013-09-01
- First posted
- 2007-03-06
- Last updated
- 2015-03-30
Locations
193 sites across 2 countries: United States, Puerto Rico
Source: ClinicalTrials.gov record NCT00443443. Inclusion in this directory is not an endorsement.